Review Articles

Resistant Hypertension and Renal Nerve Denervation



Patients with resistant hypertension are a subgroup of the hypertensive population that are at even greater risk of cardiovascular outcomes. Therapeutic options for these patients are limited to antihypertensive medications. However, renal denervation (RDN) is a novel nonpharmacologic intervention that involves a catheter-based ablation of the sympathetic nerves within the renal artery wall. The procedure initially showed promise with remarkable blood pressure reductions until the pivotal SYMPLICITY HTN-3 trial failed to demonstrate superiority of RDN over control. This trial was notable for a substantial placebo effect and an attenuated response to RDN. These findings, which contradicted those of prior studies, have raised numerous questions, including whether adequate RDN occurred in those patients. Further research is planned to resolve some of these questions and to clarify the role of RDN in treating patients with resistant hypertension.


renal denervationsympathetic nervous systemresistant hypertensionblood pressure
  • Year: 2015
  • Volume: 11 Issue: 4
  • Page/Article: 240-244
  • DOI: 10.14797/mdcj-11-4-240
  • Published on 1 Oct 2015
  • Peer Reviewed